Polyrizon
Raanana, Israel· Est.
Polyrizon builds next‑generation intranasal delivery platforms to transform how drugs reach patients.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Polyrizon builds next‑generation intranasal delivery platforms to transform how drugs reach patients.
Technology Platform
Capture & Contain (C&C) and Trap & Target (T&T) are proprietary intranasal delivery systems that capture therapeutics within the nasal cavity and actively target specific tissues to enhance bioavailability and safety.
Opportunities
Polyrizon can capitalize on the expanding market for needle‑free, rapid‑onset therapeutics, especially in respiratory, CNS, and emergency care segments.
Risk Factors
Technical challenges in achieving consistent intranasal bioavailability and navigating complex combination‑product regulatory pathways pose significant risks.
Competitive Landscape
Competitors include other intranasal delivery innovators such as Insys Therapeutics and Ocular Therapeutix; Polyrizon differentiates through its dual C&C/T&T platform and strong regulatory expertise.